TGF beta 1-Smad canonical and -Erk noncanonical pathways participate in interleukin-17-induced epithelial-mesenchymal transition in Sjogren's syndrome

TGF beta 1-Smad canonical and -Erk noncanonical pathways participate in interleukin-17-induced epithelial-mesenchymal transition in Sjogren's syndrome

Interleukin-17 (IL-17) is a pleiotropic cytokine that plays a primary role in triggering epithelial-mesenchymal transition (EMT) in many chronic inflammatory diseases. EMT plays a critical role in the progression of salivary gland (SG) fibrosis in primary Sjogren's syndrome (pSS). This study fo...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Laboratory investigation 2020-06, Vol.100 (6), p.824-836
Hauptverfasser: Sisto, Margherita, Lorusso, Loredana, Ingravallo, Giuseppe, Ribatti, Domenico, Lisi, Sabrina
Format: Artikel
Sprache:eng
Schlagworte:
Life Sciences & Biomedicine
Medicine, Research & Experimental
Pathology
Research & Experimental Medicine
Science & Technology
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 836
container_issue 6
container_start_page 824
container_title Laboratory investigation
container_volume 100
creator Sisto, Margherita
Lorusso, Loredana
Ingravallo, Giuseppe
Ribatti, Domenico
Lisi, Sabrina
description Interleukin-17 (IL-17) is a pleiotropic cytokine that plays a primary role in triggering epithelial-mesenchymal transition (EMT) in many chronic inflammatory diseases. EMT plays a critical role in the progression of salivary gland (SG) fibrosis in primary Sjogren's syndrome (pSS). This study focused on the activation of the canonical TGF-beta 1/Smad2/3 and noncanonical TGF-beta 1/Erk1/2 pathways in IL-17-dependent TGF beta 1-induced EMT in human SG epithelial cells (SGEC) derived from healthy subjects. The expression of phosphorylated Smad2/3 and Erk1/2 during IL-17 treatment-stimulated EMT was evaluated in healthy SGEC. Cotreatment with IL-17 and specific TGF beta receptor type I kinase inhibitor SB431542, or Erk 1/2 inhibitor U0126, abrogates the corresponding morphological changes and EMT phenotypic markers expression in healthy SGEC. Interestingly, inhibition of canonical TGF beta 1/Smad2/3 signal transduction had no effect on activation of the noncanonical TGF beta 1/Erk1/2/EMT pathway, suggesting that the two pathways act independently in activating IL-17-dependent EMT in SGEC. Epithelial-mesenchymal transition (EMT) plays a critical role in the progression of salivary gland (SG) fibrosis in primary Sjogren's syndrome. This study demonstrates the IL-17-dependent activation of EMT in human SG epithelial cells that occurs through both the canonical TGF-beta 1/Smad2/3 and noncanonical TGF-beta 1/Erk1/2 pathways.
doi_str_mv 10.1038/s41374-020-0373-z
format Article
fullrecord <record><control><sourceid>webofscience</sourceid><recordid>TN_cdi_webofscience_primary_000508174400001</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>000508174400001</sourcerecordid><originalsourceid>FETCH-webofscience_primary_0005081744000013</originalsourceid><addsrcrecordid>eNqVTstOwzAQtBCIhscHcPONAzKs46QJ56iFe3uvXGdLtk2cyHZUhQ_he3EkJK4gjbQzo5nRMvYg4VmCKl98JlWRCUhBgCqU-LxgiczVrKC4ZAlAqsSyVMWC3Xh_BJBZtsyv2ULJ1zRXaZ6wr-3bmu8xaC7FptM1N9r2loxuubY1Fyt34tH4dQcdmrOefCQukKGokZONCOhaHE9khSwE2Xo0WHMcKDTYkm5Fhx6taaYurgSnradA_Vzkm2P_4dA-eu4nW7u-wzt2ddCtx_ufe8ue1qtt9S7OuO8P3lBcwt3gqNNu2gFADqUssiwykOq_6fLv6YqCnt-u-tEG9Q3sHHf7</addsrcrecordid><sourcetype>Index Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>TGF beta 1-Smad canonical and -Erk noncanonical pathways participate in interleukin-17-induced epithelial-mesenchymal transition in Sjogren's syndrome</title><source>Web of Science - Science Citation Index Expanded - 2020&lt;img src="https://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg" /&gt;</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Sisto, Margherita ; Lorusso, Loredana ; Ingravallo, Giuseppe ; Ribatti, Domenico ; Lisi, Sabrina</creator><creatorcontrib>Sisto, Margherita ; Lorusso, Loredana ; Ingravallo, Giuseppe ; Ribatti, Domenico ; Lisi, Sabrina</creatorcontrib><description>Interleukin-17 (IL-17) is a pleiotropic cytokine that plays a primary role in triggering epithelial-mesenchymal transition (EMT) in many chronic inflammatory diseases. EMT plays a critical role in the progression of salivary gland (SG) fibrosis in primary Sjogren's syndrome (pSS). This study focused on the activation of the canonical TGF-beta 1/Smad2/3 and noncanonical TGF-beta 1/Erk1/2 pathways in IL-17-dependent TGF beta 1-induced EMT in human SG epithelial cells (SGEC) derived from healthy subjects. The expression of phosphorylated Smad2/3 and Erk1/2 during IL-17 treatment-stimulated EMT was evaluated in healthy SGEC. Cotreatment with IL-17 and specific TGF beta receptor type I kinase inhibitor SB431542, or Erk 1/2 inhibitor U0126, abrogates the corresponding morphological changes and EMT phenotypic markers expression in healthy SGEC. Interestingly, inhibition of canonical TGF beta 1/Smad2/3 signal transduction had no effect on activation of the noncanonical TGF beta 1/Erk1/2/EMT pathway, suggesting that the two pathways act independently in activating IL-17-dependent EMT in SGEC. Epithelial-mesenchymal transition (EMT) plays a critical role in the progression of salivary gland (SG) fibrosis in primary Sjogren's syndrome. This study demonstrates the IL-17-dependent activation of EMT in human SG epithelial cells that occurs through both the canonical TGF-beta 1/Smad2/3 and noncanonical TGF-beta 1/Erk1/2 pathways.</description><identifier>ISSN: 0023-6837</identifier><identifier>EISSN: 1530-0307</identifier><identifier>DOI: 10.1038/s41374-020-0373-z</identifier><identifier>PMID: 31925325</identifier><language>eng</language><publisher>NEW YORK: Elsevier</publisher><subject>Life Sciences &amp; Biomedicine ; Medicine, Research &amp; Experimental ; Pathology ; Research &amp; Experimental Medicine ; Science &amp; Technology</subject><ispartof>Laboratory investigation, 2020-06, Vol.100 (6), p.824-836</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>true</woscitedreferencessubscribed><woscitedreferencescount>34</woscitedreferencescount><woscitedreferencesoriginalsourcerecordid>wos000508174400001</woscitedreferencesoriginalsourcerecordid><cites>FETCH-webofscience_primary_0005081744000013</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,781,785,27929,27930,28253</link.rule.ids></links><search><creatorcontrib>Sisto, Margherita</creatorcontrib><creatorcontrib>Lorusso, Loredana</creatorcontrib><creatorcontrib>Ingravallo, Giuseppe</creatorcontrib><creatorcontrib>Ribatti, Domenico</creatorcontrib><creatorcontrib>Lisi, Sabrina</creatorcontrib><title>TGF beta 1-Smad canonical and -Erk noncanonical pathways participate in interleukin-17-induced epithelial-mesenchymal transition in Sjogren's syndrome</title><title>Laboratory investigation</title><addtitle>LAB INVEST</addtitle><description>Interleukin-17 (IL-17) is a pleiotropic cytokine that plays a primary role in triggering epithelial-mesenchymal transition (EMT) in many chronic inflammatory diseases. EMT plays a critical role in the progression of salivary gland (SG) fibrosis in primary Sjogren's syndrome (pSS). This study focused on the activation of the canonical TGF-beta 1/Smad2/3 and noncanonical TGF-beta 1/Erk1/2 pathways in IL-17-dependent TGF beta 1-induced EMT in human SG epithelial cells (SGEC) derived from healthy subjects. The expression of phosphorylated Smad2/3 and Erk1/2 during IL-17 treatment-stimulated EMT was evaluated in healthy SGEC. Cotreatment with IL-17 and specific TGF beta receptor type I kinase inhibitor SB431542, or Erk 1/2 inhibitor U0126, abrogates the corresponding morphological changes and EMT phenotypic markers expression in healthy SGEC. Interestingly, inhibition of canonical TGF beta 1/Smad2/3 signal transduction had no effect on activation of the noncanonical TGF beta 1/Erk1/2/EMT pathway, suggesting that the two pathways act independently in activating IL-17-dependent EMT in SGEC. Epithelial-mesenchymal transition (EMT) plays a critical role in the progression of salivary gland (SG) fibrosis in primary Sjogren's syndrome. This study demonstrates the IL-17-dependent activation of EMT in human SG epithelial cells that occurs through both the canonical TGF-beta 1/Smad2/3 and noncanonical TGF-beta 1/Erk1/2 pathways.</description><subject>Life Sciences &amp; Biomedicine</subject><subject>Medicine, Research &amp; Experimental</subject><subject>Pathology</subject><subject>Research &amp; Experimental Medicine</subject><subject>Science &amp; Technology</subject><issn>0023-6837</issn><issn>1530-0307</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>AOWDO</sourceid><recordid>eNqVTstOwzAQtBCIhscHcPONAzKs46QJ56iFe3uvXGdLtk2cyHZUhQ_he3EkJK4gjbQzo5nRMvYg4VmCKl98JlWRCUhBgCqU-LxgiczVrKC4ZAlAqsSyVMWC3Xh_BJBZtsyv2ULJ1zRXaZ6wr-3bmu8xaC7FptM1N9r2loxuubY1Fyt34tH4dQcdmrOefCQukKGokZONCOhaHE9khSwE2Xo0WHMcKDTYkm5Fhx6taaYurgSnradA_Vzkm2P_4dA-eu4nW7u-wzt2ddCtx_ufe8ue1qtt9S7OuO8P3lBcwt3gqNNu2gFADqUssiwykOq_6fLv6YqCnt-u-tEG9Q3sHHf7</recordid><startdate>20200601</startdate><enddate>20200601</enddate><creator>Sisto, Margherita</creator><creator>Lorusso, Loredana</creator><creator>Ingravallo, Giuseppe</creator><creator>Ribatti, Domenico</creator><creator>Lisi, Sabrina</creator><general>Elsevier</general><scope>AOWDO</scope><scope>BLEPL</scope><scope>DTL</scope></search><sort><creationdate>20200601</creationdate><title>TGF beta 1-Smad canonical and -Erk noncanonical pathways participate in interleukin-17-induced epithelial-mesenchymal transition in Sjogren's syndrome</title><author>Sisto, Margherita ; Lorusso, Loredana ; Ingravallo, Giuseppe ; Ribatti, Domenico ; Lisi, Sabrina</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-webofscience_primary_0005081744000013</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Life Sciences &amp; Biomedicine</topic><topic>Medicine, Research &amp; Experimental</topic><topic>Pathology</topic><topic>Research &amp; Experimental Medicine</topic><topic>Science &amp; Technology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sisto, Margherita</creatorcontrib><creatorcontrib>Lorusso, Loredana</creatorcontrib><creatorcontrib>Ingravallo, Giuseppe</creatorcontrib><creatorcontrib>Ribatti, Domenico</creatorcontrib><creatorcontrib>Lisi, Sabrina</creatorcontrib><collection>Web of Science - Science Citation Index Expanded - 2020</collection><collection>Web of Science Core Collection</collection><collection>Science Citation Index Expanded</collection><jtitle>Laboratory investigation</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sisto, Margherita</au><au>Lorusso, Loredana</au><au>Ingravallo, Giuseppe</au><au>Ribatti, Domenico</au><au>Lisi, Sabrina</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>TGF beta 1-Smad canonical and -Erk noncanonical pathways participate in interleukin-17-induced epithelial-mesenchymal transition in Sjogren's syndrome</atitle><jtitle>Laboratory investigation</jtitle><stitle>LAB INVEST</stitle><date>2020-06-01</date><risdate>2020</risdate><volume>100</volume><issue>6</issue><spage>824</spage><epage>836</epage><pages>824-836</pages><issn>0023-6837</issn><eissn>1530-0307</eissn><abstract>Interleukin-17 (IL-17) is a pleiotropic cytokine that plays a primary role in triggering epithelial-mesenchymal transition (EMT) in many chronic inflammatory diseases. EMT plays a critical role in the progression of salivary gland (SG) fibrosis in primary Sjogren's syndrome (pSS). This study focused on the activation of the canonical TGF-beta 1/Smad2/3 and noncanonical TGF-beta 1/Erk1/2 pathways in IL-17-dependent TGF beta 1-induced EMT in human SG epithelial cells (SGEC) derived from healthy subjects. The expression of phosphorylated Smad2/3 and Erk1/2 during IL-17 treatment-stimulated EMT was evaluated in healthy SGEC. Cotreatment with IL-17 and specific TGF beta receptor type I kinase inhibitor SB431542, or Erk 1/2 inhibitor U0126, abrogates the corresponding morphological changes and EMT phenotypic markers expression in healthy SGEC. Interestingly, inhibition of canonical TGF beta 1/Smad2/3 signal transduction had no effect on activation of the noncanonical TGF beta 1/Erk1/2/EMT pathway, suggesting that the two pathways act independently in activating IL-17-dependent EMT in SGEC. Epithelial-mesenchymal transition (EMT) plays a critical role in the progression of salivary gland (SG) fibrosis in primary Sjogren's syndrome. This study demonstrates the IL-17-dependent activation of EMT in human SG epithelial cells that occurs through both the canonical TGF-beta 1/Smad2/3 and noncanonical TGF-beta 1/Erk1/2 pathways.</abstract><cop>NEW YORK</cop><pub>Elsevier</pub><pmid>31925325</pmid><doi>10.1038/s41374-020-0373-z</doi><tpages>13</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0023-6837
ispartof Laboratory investigation, 2020-06, Vol.100 (6), p.824-836
issn 0023-6837
1530-0307
language eng
recordid cdi_webofscience_primary_000508174400001
source Web of Science - Science Citation Index Expanded - 2020<img src="https://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg" />; EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection
subjects Life Sciences & Biomedicine
Medicine, Research & Experimental
Pathology
Research & Experimental Medicine
Science & Technology
title TGF beta 1-Smad canonical and -Erk noncanonical pathways participate in interleukin-17-induced epithelial-mesenchymal transition in Sjogren's syndrome
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-14T16%3A38%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-webofscience&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=TGF%20beta%201-Smad%20canonical%20and%20-Erk%20noncanonical%20pathways%20participate%20in%20interleukin-17-induced%20epithelial-mesenchymal%20transition%20in%20Sjogren's%20syndrome&rft.jtitle=Laboratory%20investigation&rft.au=Sisto,%20Margherita&rft.date=2020-06-01&rft.volume=100&rft.issue=6&rft.spage=824&rft.epage=836&rft.pages=824-836&rft.issn=0023-6837&rft.eissn=1530-0307&rft_id=info:doi/10.1038/s41374-020-0373-z&rft_dat=%3Cwebofscience%3E000508174400001%3C/webofscience%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/31925325&rfr_iscdi=true